Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) and Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Analyst Ratings
This is a summary of recent ratings for Rhythm Pharmaceuticals and Scinai Immunotherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rhythm Pharmaceuticals | 1 | 3 | 18 | 0 | 2.77 |
| Scinai Immunotherapeutics | 1 | 0 | 0 | 0 | 1.00 |
Rhythm Pharmaceuticals currently has a consensus target price of $142.00, indicating a potential upside of 32.12%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Scinai Immunotherapeutics.
Risk and Volatility
Insider & Institutional Ownership
58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Rhythm Pharmaceuticals and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rhythm Pharmaceuticals | -69.03% | -171.16% | -43.00% |
| Scinai Immunotherapeutics | N/A | N/A | N/A |
Earnings & Valuation
This table compares Rhythm Pharmaceuticals and Scinai Immunotherapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rhythm Pharmaceuticals | $189.76 million | 39.27 | -$196.54 million | ($2.90) | -37.06 |
| Scinai Immunotherapeutics | $1.31 million | 0.41 | -$8.31 million | $8.66 | 0.05 |
Scinai Immunotherapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Scinai Immunotherapeutics beats Rhythm Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics is an Israel-based biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. Its research centers on antibody-based treatments, including compact antibody formats known as nanobodies. The company also provides research, development and manufacturing services to biotechnology and pharmaceutical companies through its Scinai BioServices business. These services support the development of biologic drugs and other products. Scinai was formerly known as BiondVax Pharmaceuticals, which worked on a universal influenza vaccine before the company shifted its focus to immunotherapies and biopharmaceutical services.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
